c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, a kinase inhibitor of FMS (Colony-stimulatingfactor-1 receptor, CSF-1R; IC50: 2 nM) with anti-tumor activity.
JTE-952 is a oral, potent active and selective Type II inhibitor of colonystimulatingfactor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse
CSF1R-IN-13 is a powerful CSF1R inhibitor with potential applications in researching cancer diseases [1]. CSF1R, also known as colonystimulatingfactor 1 receptor, is a critical growth factor that regulates various cell types, including bone marrow progenitor cells, monocytes, macrophages, and giants [1]. CSF1R-IN-13 shows promise in furthering our understanding of cancer-related disorders (WO2019134661A1, compound 32) [1].
Edicotinib, also known as JNJ-40346527, is a small molecule and orally available inhibitor of colony-stimulatingfactor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. FMS tyrosine kinase inhibitor JNJ-40346527 blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS cannot activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tumor cells.